Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

Bixlenvo clinical trials

Also listed in trial records as BIC/LEN FDC, Bictegravir/Lenacapavir (BIC/LEN) FDC
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA, Spain, Italy, UK, Germany, France, Canada, Japan, South Korea, Taiwan and Australia registers that name Bixlenvo as an intervention. Synced 28 Oct 2026
2Current trials
0Recruiting now
1Lead sponsor
11Country registers
At a glance

Bixlenvo is named as an intervention in 2 current clinical trials in our USA, Spain, Italy, UK, Germany, France, Canada, Japan, South Korea, Taiwan and Australia registers. None are recruiting at the moment. All registered phases are Phase 2/3. The lead sponsor is Gilead Sciences. The most-studied condition is HIV-1-infection.

Patient leaflets for Bixlenvo

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Active, closed2100%

Trials by phase

  • Phase 2/32100%
01

Clinical trials of Bixlenvo

2 trials
StudyPhaseStatusLead sponsorRegisters
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)
NCT05502341 · HIV-1-infection
Phase 2/3 Active, closed Gilead Sciences UK, USA, Germany, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Australia
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
NCT06532656 · HIV-1-infection
Phase 2/3 Active, closed Gilead Sciences USA, Spain, Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Bixlenvo

1 condition
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Gilead Sciences2
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA20
Clinical trials in Spain20
Clinical trials in Italy20
Clinical trials in UK10
Clinical trials in Germany10
Clinical trials in France10
Clinical trials in Canada10
Clinical trials in Japan10
Clinical trials in South Korea10
Clinical trials in Taiwan10
Clinical trials in Australia10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Bixlenvo trials

How many clinical trials are testing Bixlenvo?

2 current trials in our USA, Spain, Italy, UK, Germany, France, Canada, Japan, South Korea, Taiwan and Australia registers name Bixlenvo as a drug or biological intervention, as of the registry sync on 28 October 2026. Completed and withdrawn studies are not counted.

Are Bixlenvo trials recruiting patients?

Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors Bixlenvo clinical trials?

The lead sponsor is Gilead Sciences. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bixlenvo works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bixlenvo works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bixlenvo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.